In a novel study, Baylot et al. found that OGX-427, an antisense oligonucleotide that works as an HSP27 inhibitor, can increase the gemcitabine sensitivity in the pancreatic cancer MiaPaCa-2 cell line via decreasing the expression of eukaryotic translational initiation factor 4E (eIF4E), a downstream molecule of the mTOR pathway upregulated in numerous cancers and associated with tumor aggressiveness and chemoresistance [107]. The gene discussed is EIF4E; the disease is pancreatic neoplasm.